Loading clinical trials...

Quality of Life Model for Older Patients With AML | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

Quality of Life Model for Older Patients With AML

Development of a Quality of Life Decision-Making Model for Older Patients With Acute Myeloid Leukemia

NCT04380441•H. Lee Moffitt Cancer Center and Research Institute

Summary

The purpose of this study is to describe the differences in quality of life (QOL) among newly diagnosed patients diagnosed with acute myeloid leukemia (AML) to help design a patient decision-making QOL model for aligning patients' choice of treatment with what matters the most to them.

Eligibility

Age

60 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•60 years of age or older
•Newly diagnosed with pathology-confirmed diagnosis of Acute Myeloid Leukemia
•Within 7 days of starting a new treatment
•Must be able to read and speak English at the 8th grade level

Exclusion Criteria

•Under 60 years of age
•Other malignancy, dementia, traumatic brain injury or individuals with central nervous system involvement of their leukemia

Locations (1)

Moffitt Cancer Center

Tampa, Florida, United States

Key Dates

Start Date

July 8, 2020

Primary Completion Date

November 30, 2023

Completion Date

March 1, 2026

Last Updated

December 9, 2025

Enrollment

206

ACTUAL participants

Conditions

AML, AdultAcute Myeloid Leukemia

Phase I Study of HC-7366 for Acute Myeloid Leukemia

NCT06285890

Acute Myeloid Leukemia

View study

RECRUITINGPHASE2

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

NCT06220162

Acute Myeloid Leukemia

View study

RECRUITINGPHASE1/PHASE2

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

NCT04065399

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 9, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Quality of Life Model for Older Patients With AML

Inclusion Criteria

Exclusion Criteria

Phase I Study of HC-7366 for Acute Myeloid Leukemia

VAC Regimen for AML Patients Who Failed to Response to VA Regimen

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2